 Dr. Paul Vanhoutte MD, Ph.D. is co-chairman of Entia's SAB.
He is currently Chair Professor at the Department of Pharmacology and Pharmacy at the Li Ka Shing Faculty of Medicine, University of Hong Kong, China and is director of that distinguished institution’s BioPharmaceutical Development Center.
Prior to his move to Asia in 2003, Dr. Vanhoutte was Vice President of Research and Development at the Institut de Recherches Internationales Servier, Courbevoie, France (1992-2002), Director of the Center for Experimental Therapeutics, Department of Medicine, Baylor College of Medicine, Houston, Texas (1989-1995), and Consultant to the Department of Physiology and Biophysics and Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota (1981-1989).
 Dr. Jack Rogers Ph.D. has focused lab studies on iron metabolism and how it impacts certain disease processes such as anemia and Alzheimer's disease. His scientific focus has been to study the translational regulation of the mRNAs for the Alzheimer's Amyloid Precursor Protein (APP) and the subunits of the iron storage protein ferritin.
Currently his research is directed toward understanding how RNA structure controls APP-mRNA translational regulation relevant to neurodegenerative diseases including Alzheimer's disease and Down's syndrome. The APP-mRNA 5'UTR mediates increased APP synthesis and amyloid peptide secretion from astrocytes in response to inflammation. Genetic approaches are being used to explain how the 5' untranslated region (5'UTR) of APP mRNA operates as a translational control element in neuronal and astrocytic cells. In collaboration with Message Pharmaceuticals, his laboratory have developed a project to use small RNA-binding drugs to suppress APP-mRNA translation from the 5'UTR stem-loop, and thereby develop new therapeutic strategies to inhibit A Beta-peptide secretion and amyloid plaque build-up.
Iron chelation also controls APP gene expression at the translational level. Dr. Rogers’ laboratory recently discovered the existence of an Iron-regulatory domains in the APP-mRNA 5'UTR. This result led to investigations on how iron metabolism might be important for the function of APP. To follow-up on this finding, his laboratory is examining whether APP over-expression enhances iron uptake into cultured cells and whether secreted APP is a copper-dependent ferroxidase.
Dr. Rogers has several ongoing collaborative projects including examining whether iron and inflammation regulate ferritin gene expression and translation in liver cells (Dr. K Bridges, Brigham and Women's Hospital Boston) and how thyroid hormone and Thyroid-Releasing Hormone cooperatively increase ferritin gene expression in Pituitary cells (Dr. P. Leedman Univ. Perth Western Australia).
View Complete C.V. | Click Here
 Dr. Krishna Bhat MD, Ph.D. is a Professor of Neurosciences at University of Texas Medical Branch School of Medicine in Texas. His team studies the development, function and disease of the brain using the model system Drosophila melanogaster. His group has identified a number of genes that regulate neuronal identity specification, asymmetric division of neural stem cells, axon guidance and adult brain development.
On the disease side, his team works mainly on the Alzheimer’s disease using the Drosophila model of the disease, including drug discovery, as well as obesity. His group has done groundbreaking work on how stem cells undergo asymmetric division, and also has isolated thousands of conditional mutants, an accomplishment that has never been achieved before. Krishna was trained at Memorial University in Canada, Princeton University in the US and University of Cagliari in Italy. Originally from India, his work is primarily funded by National Institutes of Health.
 Dr. Catherine Cahill Ph.D. is an assistant in Biology in the department of Pediatrics at Massachusetts General Hospital. Dr. Cahill is an active researcher at Harvard focusing on gene regulation and inflammatory diseases.
Her current focus in Mucosal Immunology at MGH is gene regulation and signal transduction downstream of IL-1β in the intestinal epithelium. The Caco-2 cell is an intestinal epithelial adenocarcinoma capable of forming polarized monolayers with similar characteristics to the intestinal epithelium. Dr. Cahill has identified a novel PI3-K dependent signaling pathway in this cell, downstream of the IL-1 receptor, involved in AP-1 activation and interleukin-6 gene transcription.
 Dr. Jack Vanden Heuvel Ph.D. is professor of Molecular Toxicology at Penn State University. He is also the founder and chief scientific officer of Indigo Biosciences, Inc. Dr. Vanden Heuvel received his B.S. in Pharmacology/Toxicology and his Ph.D. in Environmental Toxicology from University of Wisconsin-Madison. His research interests include focusing on nuclear receptors acting as intracellular transcription factors that directly regulate gene expression in response to lipophilic molecules.
View Complete CV | Click Here
 Dr. Daniel Royse Ph.D. is professor, mushroom extension specialist, and director at the mushroom spawn laboratory in the department on plant pathology at Pennsylvania State University. He has extensive research experience specializing in germplasm enhancement of cultivated mushrooms, biological efficiency of cultivated mushrooms and the development of advanced technology for the cultivation of specialty varieties.
 Dr. Penny Kris-Etherton, Ph.D., R.D. is the distinguished professor of Nutrition in the Department of Nutrition Sciences at Penn State University. Dr. Kris-Etherton’s research expertise is cardiovascular nutrition. She has published over 200 scientific papers, 25 book chapters, and co-authored four books. For over 20 years, she has conducted many controlled clinical nutrition studies designed to evaluate the role of diet on risk factors for cardiovascular disease (CVD). These studies have evaluated established and emerging CVD risk factors including lipids, lipoproteins, blood pressure, inflammatory markers and adhesion molecules. Dr. Kris-Etherton has served on many national committees and review panels including the 2005 Dietary Guidelines for Americans Advisory Committee, the National Academy of Sciences Panel on Macronutrients, NIH's Nutrition Study Section, the National Cholesterol Education Program Second Adult Treatment Panel, and the ASCN/AIN Task Force on Trans Fatty Acids. She has held numerous editorial board appointments, including journals such as Journal of Clinical Lipidology, Lipids, Current Atherosclerosis Reports, American Journal of Clinical Nutrition, Journal of the American Dietetic Association, Journal of Nutrition Education, and International Journal of Sports Nutrition.
 Dr. Debomoy Lahiri Ph.D. is Professor in the Department of Psychiatry and of Medical & Molecular Genetics and full member of the Stark Neurosciences Research Institute at the Indiana University (IU) School of Medicine, Indianapolis. Currently, he is Chief of the Laboratory of Molecular Neurogenetics at the Institute of Psychiatric Research of IU School of Medicine. Prior to joining Indiana University, Dr. Lahiri was a faculty member at Mount Sinai School of Medicine, New York, NY. His particular research interest is in understanding the mechanism of aging; origin and biogenesis of the amyloid plaque and gene regulation of Alzheimer's disease (AD). Further, Dr. Lahiri’s group has recently shown beneficial effects of dietary nutrients, such as aged garlic extract (AGE), S-Ally cysteine (SAC), curcumin, nanocurmin in neuropreservation and neuroproteiction, which have far reaching implications in man’s health and longevity.
Dr. Lahiri has been awarded multiple research grants as a Principal Investigator from the National Institute on Aging, National Institutes of Health (NIH) and Alzheimer's Association. Dr. Lahiri is a member of the NIH study section, of the Scientific Advisory Board for the Institute for the Study of Aging, New York, for QR Pharma, Philadelphia and for Yuma Therapeutics, Boston. He has published over 250 scientific papers in the field of neurobiology, genetics and AD (including high impact factor journals, such as JBC, PNAS, FASEB J, JPET, Neuron, and Nature Neurosci Rev and Science). Dr. Lahiri is the Editor-In-Chief of the international journal, ‘Current Alzheimer Research', which is listed in MEDLINE/PubMed (www.benthamscience.com/car). He has also coauthored books, such as ‘Protective Strategies for Neurodegenerative Diseases' published by the New York Academy of Sciences. Dr. Lahiri's honors include the listing in Marquis' ‘Who's Who in the World', and receiving the prestigious ‘Zenith Award' from Alzheimer's Association.
 Dr. Dirk Gründemann Ph.D. was born in Hameln, Germany. He has been a member of the group of H, Koespsell, Max-Planck-Institute of Biophysics in Frankfurt, Germany since 1991. Dr. Gründemann's post doc research was exercised with the group of E. Schömig in the department of Pharmacology at the University of Heidelberg. Since 2001 he has performed research at the University of Cologne, Germany in the department of Pharmacology and became professor in 2006. Dr. Gründemann was a discoverer of the Ergothioneine transporter (ETT) and has dedicated much of his research into the properties and benefits of ergothioneine. Other research topics include restriction enzyme Eco RI, non-neuronal monoamine transport proteins (OCT1, OCT2, EMT), membrane-inserted transport proteins, LC-MS and glutamate efflux transporter (OAT2).
 Dr. Hector Rodriguez MD, Ph.D. is the medical director for Davita with a focus on anemia, diabetes and kidney disease. He has practiced Nephrology and Internal Medicine for 40 years in Beverly Hills, California. Dr. Rodriguez attended Universidad Nacional De Colombia, Facultad De Medicina in Santa Fe De Bogota, Colombia and graduated in 1967.
|
